Alice Tzeng1, C Marcela Diaz-Montero2, Patricia A Rayman2, Jin S Kim2, Paul G Pavicic2, James H Finke2, Pedro C Barata3, Marcelo Lamenza3, Sarah Devonshire3, Kim Schach3, Hamid Emamekhoo4, Marc S Ernstoff5, Christopher J Hoimes6, Brian I Rini3, Jorge A Garcia3, Timothy D Gilligan3, Moshe C Ornstein7, Petros Grivas8,9. 1. Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA. 2. Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. 3. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Division of Hematology and Medical Oncology, University of Wisconsin, Madison, WI, USA. 5. Roswell Park Cancer Institute, Buffalo, NY, USA. 6. University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. 7. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. ornstem@ccf.org. 8. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. pgrivas@uw.edu. 9. Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA. pgrivas@uw.edu.
Abstract
BACKGROUND: The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE: We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor cells [MDSC]; cytotoxic T lymphocytes [CTL]) following ICI therapy and investigated whether these changes correlated with outcomes in patients with metastatic urothelial carcinoma (mUC). PATIENTS AND METHODS: Serial peripheral blood samples were collected from ICI-treated mUC patients. Flow cytometry was used to quantify PD1/PDL1 expression on MDSC (CD33+HLADR-) and CTL (CD8+CD4-) from peripheral blood mononuclear cells. MDSC were grouped into monocytic (M)-MDSC (CD14+CD15-), polymorphonuclear (PMN)-MDSC (CD14-CD15+), and immature (I)-MDSC (CD14-CD15-). Mixed-model regression and Wilcoxon signed-rank or rank-sum tests were performed to assess post-ICI changes in immune biomarker expression and identify correlations between PD1/PDL1 expression and objective response to ICI. RESULTS: Of 41 ICI-treated patients, 26 received anti-PDL1 (23 atezolizumab/3 avelumab) and 15 received anti-PD1 (pembrolizumab) therapy. Based on available data, 27.5% had prior intravesical Bacillus Calmette-Guérin therapy, 42% had prior neoadjuvant chemotherapy, and 70% had prior cystectomy or nephroureterectomy. Successive doses of anti-PDL1 correlated with decreased percentage of PDL1+ (%PDL1+) M-MDSC, while doses of anti-PD1 correlated with decreased %PD1+ M- and I-MDSC. Although pre-treatment %PD1+ CTL did not predict response, a greater %PD1+ CTL within 9 weeks after ICI initiation correlated with objective response. CONCLUSIONS: Treatment with ICI correlated with distinct changes in PD1/PDL1-expressing peripheral immune cell subsets, which may predict objective response to ICI. Further studies are required to validate immune molecular expression as a prognostic and/or predictive biomarker for long-term outcomes in mUC.
BACKGROUND: The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE: We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor cells [MDSC]; cytotoxic T lymphocytes [CTL]) following ICI therapy and investigated whether these changes correlated with outcomes in patients with metastatic urothelial carcinoma (mUC). PATIENTS AND METHODS: Serial peripheral blood samples were collected from ICI-treated mUC patients. Flow cytometry was used to quantify PD1/PDL1 expression on MDSC (CD33+HLADR-) and CTL (CD8+CD4-) from peripheral blood mononuclear cells. MDSC were grouped into monocytic (M)-MDSC (CD14+CD15-), polymorphonuclear (PMN)-MDSC (CD14-CD15+), and immature (I)-MDSC (CD14-CD15-). Mixed-model regression and Wilcoxon signed-rank or rank-sum tests were performed to assess post-ICI changes in immune biomarker expression and identify correlations between PD1/PDL1 expression and objective response to ICI. RESULTS: Of 41 ICI-treated patients, 26 received anti-PDL1 (23 atezolizumab/3 avelumab) and 15 received anti-PD1 (pembrolizumab) therapy. Based on available data, 27.5% had prior intravesical Bacillus Calmette-Guérin therapy, 42% had prior neoadjuvant chemotherapy, and 70% had prior cystectomy or nephroureterectomy. Successive doses of anti-PDL1 correlated with decreased percentage of PDL1+ (%PDL1+) M-MDSC, while doses of anti-PD1 correlated with decreased %PD1+ M- and I-MDSC. Although pre-treatment %PD1+ CTL did not predict response, a greater %PD1+ CTL within 9 weeks after ICI initiation correlated with objective response. CONCLUSIONS: Treatment with ICI correlated with distinct changes in PD1/PDL1-expressing peripheral immune cell subsets, which may predict objective response to ICI. Further studies are required to validate immune molecular expression as a prognostic and/or predictive biomarker for long-term outcomes in mUC.
Authors: Lawrence F Kuklinski; Shaofeng Yan; Zhongze Li; Jan L Fisher; Chao Cheng; Randolph J Noelle; Christina V Angeles; Mary Jo Turk; Marc S Ernstoff Journal: Cancer Immunol Immunother Date: 2018-05-08 Impact factor: 6.968
Authors: Neeraj Agarwal; Sumanta K Pal; Andrew W Hahn; Roberto H Nussenzveig; Gregory R Pond; Sumati V Gupta; Jue Wang; Mehmet A Bilen; Gurudatta Naik; Pooja Ghatalia; Christopher J Hoimes; Dharmesh Gopalakrishnan; Pedro C Barata; Alexandra Drakaki; Bishoy M Faltas; Lesli A Kiedrowski; Richard B Lanman; Rebecca J Nagy; Nicholas J Vogelzang; Kenneth M Boucher; Ulka N Vaishampayan; Guru Sonpavde; Petros Grivas Journal: Cancer Date: 2018-03-08 Impact factor: 6.860
Authors: Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton Journal: Cancer Immunol Immunother Date: 2011-06-05 Impact factor: 6.968
Authors: Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo Journal: Cancer Discov Date: 2016-06-14 Impact factor: 39.397
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero Journal: Cancer Immunol Immunother Date: 2008-04-30 Impact factor: 6.968
Authors: Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin Journal: Lancet Date: 2016-12-08 Impact factor: 79.321
Authors: Kirsten Ridder; Alexandra Sevko; Janina Heide; Maria Dams; Anne-Kathleen Rupp; Jadranka Macas; Julia Starmann; Marc Tjwa; Karl H Plate; Holger Sültmann; Peter Altevogt; Viktor Umansky; Stefan Momma Journal: Oncoimmunology Date: 2015-03-19 Impact factor: 8.110
Authors: Kathryn E Cole; Quan P Ly; Michael A Hollingsworth; Jesse L Cox; Kurt W Fisher; James C Padussis; Jason M Foster; Luciano M Vargas; James E Talmadge Journal: Int Immunopharmacol Date: 2022-02-21 Impact factor: 4.932
Authors: Joanna Roopkumar; Shadi Swaidani; Ann S Kim; Bicky Thapa; Lorenzo Gervaso; Brian P Hobbs; Wei Wei; Tyler J Alban; Pauline Funchain; Suman Kundu; Naseer Sangwan; Patricia Rayman; Paul G Pavicic; C Marcela Diaz-Montero; John Barnard; Keith R McCrae; Alok A Khorana Journal: Med (N Y) Date: 2021-03-12
Authors: Tian Zhang; Michael R Harrison; Peter H O'Donnell; Ajjai S Alva; Noah M Hahn; Leonard J Appleman; Jeremy Cetnar; John M Burke; Mark T Fleming; Matthew I Milowsky; Amir Mortazavi; Neal Shore; Guru P Sonpavde; Emmett V Schmidt; Bojena Bitman; Veerendra Munugalavadla; Raquel Izumi; Priti Patel; Janet Staats; Cliburn Chan; Kent J Weinhold; Daniel J George Journal: Cancer Date: 2020-08-05 Impact factor: 6.860